NICE to assess cancer and heart treatments next

The National Institute for Clinical Excellence's next work programme will consider of treatments for cancer and heart disease. Thrombolytic drugs for heart attacks, caelyx for ovarian cancer and STI-571 for chronic myeloid leukaemia will be appraised. Other treatments NICE will consider in the next wave will include surgical procedures for ...

You need to be signed in to read more


Subscribe for unlimited access

With a HSJ subscription you’ll unlock:

  • All of and our HSJ mobile app
  • News and insight on all areas of public funded healthcare
  • Expert commentary, insight and analysis from industry leaders
  • 9 weekly ‘Expert Briefing’ insight emails covering a variety of specialist topics

Sign into your account here